Skip to content

Evidence

Latest FreedomWitness coverage in this editorial section.

Evidence analysis

Artificial intelligence in medicine regulation: from concept to practice

Privacy & Data: Artificial Intelligence in Medicine Regulation – From Concept to Practice What is established The European Medicines Agency (EMA) and the European medicines regulatory network are actively integrating artificial intelligence (AI) technologies into medicine regulation processes.…

Read →

Evidence analysis

Artificial intelligence

Privacy & Data in Artificial Intelligence for Medicine Regulation: An Evidence Dossier What is established The European Medicines Agency (EMA) is actively integrating artificial intelligence (AI) technologies into medicine regulation within Europe. This involves developing and deploying AI-driven…

Read →

Evidence analysis

Hope for World’s Forests and Their Defenders at COP31

Evidence Dossier: Hope for World’s Forests and Their Defenders at COP31 What is established At the COP31 United Nations Climate Change Conference held in November 2026 in Antalya, Türkiye, a significant financial commitment was made by the Netherlands…

Read →

Evidence analysis

Türkiye: COP31 Host Continues Support for Coal Expansion

What is established Türkiye hosted the United Nations climate change conference, COP31, in Antalya on November 11–12, 2026. During this major international event, global leaders gathered to discuss accelerating action against climate change and fulfilling climate commitments. Despite…

Read →

Evidence analysis

Bosnian Raids Smash Two Crime Rings, Net 15 Arrests

Human Rights and Organized Crime in Bosnia: Evidence Dossier What is established On November 11, 2026, Bosnian authorities conducted a large-scale operation targeting two organized crime groups. The Ministry of Interior for Zenica-Doboj Canton announced the arrest of…

Read →

Evidence analysis

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 31, Status: Authorised

What is established Flixabi is a biosimilar medicine containing infliximab, a monoclonal antibody targeting tumour necrosis factor-alpha (TNF-alpha), an inflammatory protein elevated in conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.…

Read →